Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
2008

Combining Inositol Hexakisphosphate and Proteasome Inhibitors to Kill Prostate Cancer Cells

publication 10 minutes Evidence: moderate

Author Information

Author(s): Diallo J-S, Betton B, Parent N, Péant B, Lessard L, Le Page C, Bertrand R, Mes-Masson A-M, Saad F

Primary Institution: Centre de recherche du Centre hospitalier de l'Université de Montréal (CR-CHUM) and Institut du cancer de Montréal

Hypothesis

The upregulation of NF-κB-responsive genes and pro-apoptotic proteins could mediate the pro-apoptotic effects of inositol hexakisphosphate (IP6) in prostate cancer cells.

Conclusion

The study suggests that combining inositol hexakisphosphate with proteasome inhibitors enhances the cytotoxic effects on androgen-independent prostate cancer cells.

Supporting Evidence

  • IP6 treatment led to increased levels of pro-apoptotic proteins in prostate cancer cells.
  • Combining IP6 with proteasome inhibitors significantly enhanced cell death compared to either treatment alone.
  • Blocking protein translation reduced the effectiveness of IP6, indicating the importance of protein synthesis in its action.

Takeaway

Researchers found that a natural compound called inositol hexakisphosphate can help kill prostate cancer cells, especially when used with certain cancer drugs that block protein breakdown.

Methodology

The study involved treating prostate cancer cell lines with inositol hexakisphosphate and proteasome inhibitors, followed by various assays to measure cell viability and protein expression.

Limitations

The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.

Statistical Information

P-Value

p<0.005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6604730

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication